Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > MYCO

<< Previous

Bullboard Posts

Next >>

Comment by TeddyTenBagson Feb 07, 2021 10:41am

195 Views

Post# 32495461

RE:RE:MYCO

I think the people on this board (and others) don't understand that a stock price is reflective of the valuation of a company, which a stock split literally does nothing to change that. Whether you have a 1 share at $1,000 or 1,000 at $1, it's still $1,000 at the end of the day.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth